JPMorgan analyst Cory Kasimov maintains Overweight on Ultragenyx Pharma (NASDAQ: RARE).The analyst believes the announcement that UX007 can be filed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE